Show/Hide Menu


MOR202 is a fully human monoclonal HuCAL-antibody directed against CD38, a therapeutic target for the treatment of multiple myeloma (MM) and certain leukemias. 

Multiple myeloma (MM) is seldom curable and a majority of patients experience a relapse after initial responses. This has led to a particularly high demand for alternative treatments, such as those that target the CD38 surface antigen. CD38 is one of the most strongly and uniformly expressed antigens on the surface of malignant plasma cells, and is an established diagnostic marker for multiple myeloma. MOR202 induces antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) mediated killing of multiple myeloma cells.

Mode of action

Clinical Studies

MOR202 is currently under clinical investigation in a phase 1/2a trial* in patients with relapsed/refractory multiple myeloma (MM). Here you can find further information on the active clinical trial.


*Supported by the German Federal Ministry of Education and Research as part of Munich's leading edge cluster m4 - Personalized medicine and targeted therapies

Poster clinical data of MOR202 presentet at 2017 ASCO Annual Meeting
(PDF, 728 KB)
Poster clinical data of MOR202 presented at 2016 DGHO Annual Meeting
(PDF, 232 KB)
Poster clinical data of MOR202 presented at the 2016 EHA Conference
(PDF, 1.5 MB)
Poster clinical data of MOR202 presented at 2016 ASCO Annual Meeting
(PDF, 203 KB)